What is HC Wainwright’s Forecast for IN8bio FY2024 Earnings?

IN8bio, Inc. (NASDAQ:INAB) – HC Wainwright issued their FY2024 earnings per share (EPS) estimates for shares of IN8bio in a note issued to investors on Wednesday, November 13th. HC Wainwright analyst S. Ramakanth anticipates that the company will post earnings of ($0.59) per share for the year. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for IN8bio’s current full-year earnings is ($0.52) per share. HC Wainwright also issued estimates for IN8bio’s Q4 2024 earnings at ($0.08) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.07) EPS, Q3 2025 earnings at ($0.06) EPS, Q4 2025 earnings at ($0.05) EPS, FY2025 earnings at ($0.26) EPS, FY2026 earnings at ($0.28) EPS, FY2027 earnings at ($0.17) EPS and FY2028 earnings at $0.54 EPS.

IN8bio Stock Up 6.1 %

Shares of NASDAQ:INAB opened at $0.34 on Friday. The business has a fifty day moving average of $0.30 and a 200-day moving average of $0.68. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.66 and a current ratio of 1.84. IN8bio has a twelve month low of $0.22 and a twelve month high of $2.48.

Institutional Trading of IN8bio

A hedge fund recently raised its stake in IN8bio stock. Sigma Planning Corp grew its position in IN8bio, Inc. (NASDAQ:INAB) by 42.0% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 851,280 shares of the company’s stock after buying an additional 251,600 shares during the period. Sigma Planning Corp owned 1.82% of IN8bio worth $230,000 at the end of the most recent reporting period. Institutional investors own 92.05% of the company’s stock.

About IN8bio

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.